中国医学现代化中的等价性:对配方颗粒中的活性成分,加工方法和临床结果的多维分析
Bo Xie1, Xi Qu1, Huijing Shi1
1Department of Obstetrics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Drug discoveries & therapeutics
|March 1, 2026
概括
由于制造变化和有限的临床证据,中国草药配方颗粒可能不等同于传统的. 需要更多的研究来确保它们的质量和治疗等价性,以获得国际认可.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分析化学 分析化学
- 传统中国医药 传统中国医药
背景情况:
- 中国草药配方颗粒旨在取代传统的,但面临着制造方面的挑战.
- 处理导致挥发性油的损失,可热性化合物的降解,以及未知的梅拉德反应产物的形成.
- 目前的质量控制依赖于有限的标记物和不一致的指纹分析,不充分评估复杂的草本系统.
研究的目的:
- 评估用中国草药配方颗粒替代传统片的可行性.
- 评估配方颗粒和传统的化学和治疗等价性.
- 发现配方颗粒的研究和质量控制方面的差距.
主要方法:
- 使用了先进的分析技术,如超高性能液体色谱四极飞行时间质谱法 (UPLC-Q-TOF-MS).
- 审查了生物等价性研究,比较了体外性能,曲线下的面积 (AUC) 和Cmax值.
- 分析了临床研究的可用性和质量,包括随机对照试验 (RCT).
主要成果:
- 配方颗粒在制造过程中经历了大量挥发性油的损失 (<30%) 和活性成分的降解.
- 生物等价性研究显示,与传统相比,体外性能变化 (60-90%) ,关键成分含量存在差异.
- 高化学相似性不能保证治疗等价性,强有力的临床证据,特别是对比RCT,很少 (<5%的研究).
结论:
- 由于制造过程引起的成分变化,中国草药配方颗粒与传统的等价性是可疑的.
- 目前的质量控制和生物等价性评估不足以确定治疗等价性.
- 未来的研究重点包括开发保存挥发性成分的方法,评估协同效应,并进行大规模临床试验,以确保科学可信度和接受度.
相关概念视频
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
387
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
387
01:26Pharmaceutical Equivalents
234
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
234
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
01:16Bioequivalence: Overview
2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
217
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
217